immunocoreIMCR_CorporateDeck_January2023_vFinal.pdf

1、Transformative Medicines for PatientsJANUARY 2023This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Words such as“may,”“can,”“will,”“believe,”“expect,”“plan,”“anticipate,”“potential”and similar expressions(as well as other

2、 words or expressions referencing future events or circumstances)are intended to identify forward-looking statements.All statements,other than statements of historical facts,included in this presentation are forward-looking statements.These statements include,but are not limited to,statements regard

3、ing the marketing,therapeutic potential,and expected clinical benefits,including extended overall survival benefit and reduction in circulating tumor DNA,of Immunocores products and product candidates;expectations regarding the development of Immunocores pipeline and the design,progress,timing,enrol

4、lment,scope,expansion and results of Immunocores existing,planned and other future clinical trials and IND enabling studies,including the targeted delivery of IND for three new product candidates,the expansion of,and timing for reporting data from the monotherapy and combination arms of,the PRAME-A0

5、2 trial and the timing for reporting data from the single ascending dose portion of the IMC-M113V Phase 1 HIV clinical trial;the ability of TCR therapeutics to target 90%of the human proteome;statements regarding the durability,efficacy and toleration of Immunocores product candidates;expectations r

6、egarding the commercialization of KIMMTRAK including potential growth opportunities and trends and increasing access to KIMMTRAK;expectations regarding the value proposition of KIMMTRAK in metastatic uveal melanoma(mUM)and advanced melanoma;expectations regarding the potential market size and opport